Answer

Drivers of Scent recovery, 2H evolution (Fine Fragrance vs. Consumer Fragrance), and the R&D plan to support 2027 (IFF)

1) Drivers of the Scent recovery

Based on management’s commentary in the 2026 Q2 earnings transcript, the Scent recovery is being supported by a combination of (a) operating turnaround efforts in R&D and go-to-market, (b) stabilization/recovery dynamics in Fine Fragrance despite Middle East-related uncertainty, and (c) stronger underlying performance in Fragrance Ingredients and Consumer Fragrance execution.

A. R&D “pipeline” rebuilt after being behind; stronger capability today

Management explicitly describes a multi-year R&D capability build:

The “R&D pipeline” “2.5 years ago… was not what it should have been,” but today the company claims a “very strong R&D capability,” “great perfumers,” “leading-edge new Fine Fragrances and Consumer Fragrances,” and “a great pipeline of molecules as well as delivery systems.” ¹
This matters for recovery because it signals the company is no longer relying primarily on short-term fixes; instead it is rebuilding the product creation and ingredient/delivery capabilities that feed customer wins and market share.

B. Market share gains and a strengthened go-to-market approach in Consumer Fragrance

On Scent’s “recovery” framing, management ties progress to:

“compounds” work, rebuilding “the R&D capability,” rebuilding “go-to-market approach with customers,” and “trying to drive market share gains” in Consumer Fragrance. ²

C. Fine Fragrance: managed volatility from the Middle East; recovery expected to become clearer into Q4

Fine Fragrance is described as facing “noise due to the Middle East conflict on Fine Fragrances,” but the execution has been to manage volatility rather than accept deterioration:

Fine Fragrance “challenges in the Middle East” were managed such that growth finished “up slightly positive” versus an expectation of “down in Fine Fragrance mid-single digits.” ³
Management also characterizes the near-term as: “a softer Q3” with recovery “as we get to Q4 overall.” ³

D. Fragrance Ingredients strength acts as an important near-term tailwind (and is expected to normalize)

Although the question focuses on Fine/Consumer Fragrance evolution, the Scent recovery is also supported by Fragrance Ingredients (which management treats as part of the Scent segment performance drivers):

Scent delivered Q2 growth “Sales were up 8%,” driven “a key driver… was the Fragrance Ingredients business,” which “grew north of 20%.” ³
The growth included favorable comparisons (“comparing to a down 10% or more in the year ago period”) and use of the synthetics portfolio to capture sales amid “macro… including… supply chain disruptions and higher Brent crude prices.” ³
Management expects normalization: “As things will settle down, we do expect it will normalize,” with the forecast for 2H including growth shifting “back towards the higher value-added ingredients versus the traditional synthetics.” ³

Bottom line: the recovery narrative is a blend of (1) R&D capability rebuilding and product pipeline improvement, (2) managed Fine Fragrance volatility with Q4 recovery dynamics, and (3) strong near-term momentum from Fragrance Ingredients and Consumer Fragrance rebuilding to support market share and customer wins.

2) How Fine Fragrance and Consumer Fragrance are expected to evolve in the second half (2026)

Fine Fragrance (2H trajectory)

Management’s guidance for Fine Fragrance in the second half is structured as Q3 softness, Q4 strength:

“Fine Fragrance… will be a little bit softer in Q3, but a stronger Q4,” implying “a second half basis in the mid-single-digit range.” ²
This view is consistent with the earlier point that the Middle East impact remains, but recovery visibility improves later:
Management indicates they are “factoring in a softer Q3” and then “really start to see some recovery as we get to Q4.” ³

Consumer Fragrance (2H trajectory)

Consumer Fragrance is expected to be in low single digits and to “normalize” after a strong Q2:

“On the Consumer Fragrance side… you’re in that low single-digit range.” ²
They note Q2 was “a really good Q2 at a high single-digit number,” which they “expect… will normalize… to… a low single-digit number” “on a go-forward basis.” ²

Fragrance Ingredients (important context for Scent recovery, and influences consolidated tone)

While the question asks Fine vs. Consumer Fragrance, management also flags that Ingredients will normalize and face some pressure year-over-year:

Fragrance Ingredients “was very strong in Q2,” and management expects “normalize… on a go-forward basis,” “slightly under pressure in terms of year-over-year performance.” ²

Summary table (directional evolution, using management’s language)

Scent sub-business	Expected 2H evolution (2026)	Evidence from excerpts
Fine Fragrance	Softer Q3, stronger Q4; 2H mid-single digits	“softer in Q3, but a stronger Q4… mid-single-digit range” ² and “softer Q3… start to see some recovery… Q4” ³
Consumer Fragrance	Normalize from high single digits (Q2) to low single digits; low single-digit baseline	“low single-digit range… high single-digit number… will normalize… to… low single-digit” ²
Fragrance Ingredients	Normalize; slightly under pressure YoY; shift back to higher-value natural products (longer glide)	“normalize… slightly under pressure… shift… to higher-value natural products… underway” ² and “growth… will shift back towards… higher value-added… versus… traditional synthetics” ³

3) Plan for R&D to support 2027 (what the company says it is doing)

The excerpts do not provide a line-by-line “2027 R&D budget plan,” but they do clearly describe the R&D capability status and the mechanisms management believes will underpin 2027.

A. R&D capability and pipeline are now “strong,” enabling execution through 2027

Management states that after being behind 2.5 years ago, the company now has:

“a very strong R&D capability,” “great R&D team,” “great perfumers” developing “leading-edge new Fine Fragrances and Consumer Fragrances,” and “a great pipeline of molecules as well as delivery systems.” ¹

This indicates the plan for 2027 is centered on capability readiness and pipeline continuity rather than rebuilding from scratch.

B. Compounds/product platform and delivery systems are part of the execution engine

Management ties Consumer Fragrance recovery to “good job on the compounds,” plus “rebuild the R&D capability” and “go-to-market approach.” ²
Separately, R&D progress is described in terms of “pipeline of molecules as well as delivery systems.” ¹
Together, these imply that for 2027, the company expects its R&D platform (molecules + delivery systems + compounds) to translate into customer innovations and stronger competitive positioning.

C. Ingredients strategy (higher-value natural products) takes longer—positioning improvement “next year and the year after”

Management distinguishes between second-half 2026 and later years for Ingredients transformation:

The shift to “higher-value natural products” “will take a little bit more time,” “not in the second half of this year,” but “as we go into next year and the year after,” management “believe[s] we’ll have a really strong competitive position.” ²

That is effectively the company’s medium-term R&D/innovation payoff window leading into 2027 (and beyond).

D. R&D is embedded in a broader “reinvent and reinvest” cycle tied to innovation and market share

Management frames reinvestment in innovation as a key pillar and indicates a sustained level of reinvestment:

They reference R&D as a percentage of sales being in an “8% to 9% range,” emphasizing the need to “critically continue to reinvest… because it becomes that circle where we make those investments, we get the better growth rate… expand margin, but continue to reinvest.” ⁴

While the statement is not explicitly “for 2027 only,” it is the clearest explicit “plan” style indication in the excerpts for how R&D will be supported going forward, consistent with supporting 2027 outcomes.

Integrated answer (directly to the question)

Drivers of Scent recovery: management points to rebuilt/strengthened R&D capability and pipeline (molecules + delivery systems + leading-edge perfumery), rebuilding Consumer Fragrance go-to-market and compounds work to drive market share gains, managing Fine Fragrance Middle East volatility (slightly positive in Q2 vs. expectations of decline), and near-term tailwinds from Fragrance Ingredients strength that will normalize and shift toward higher-value ingredients. ²¹³
Second half evolution (2026):
- Fine Fragrance: softer in Q3, stronger in Q4, with 2H in the mid-single-digit growth range. ²³
- Consumer Fragrance: expected to be low single digit, normalizing from a high single-digit Q2 to a low single-digit go-forward rate. ²
R&D plan to support 2027: management describes a materially improved R&D engine (strong capability, perfumers, and pipeline) and links it to innovation outcomes; it also indicates that the higher-value Ingredients competitive position payoff is expected “next year and the year after” (i.e., aligning with 2027) while maintaining sustained reinvestment levels in R&D (8%–9% of sales described). ²¹⁴

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

Keep Reading

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.

Sources used

Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?

Answer outline

Drivers of Scent’s recovery (what management attributes the turnaround to)
- Rebalancing and targeted reinvestment in Scent capabilities
- R&D pipeline and leadership reset (the “capability” driver)
- Fine Fragrance vs. Middle East volatility (a major near-term driver of the recovery path)
- Consumer Fragrance execution: rebuilding R&D and go-to-market to win share
- Fragrance Ingredients: strong Q2 performance, then normalization and mix shift
How Fine Fragrance and Consumer Fragrance will evolve in 2H 2026 (management’s directional growth view)
- Fine Fragrance (soft Q3, stronger Q4; trajectory into 2H mid-single digits)
- Consumer Fragrance (low single-digit normalization; Q2 was strong but should normalize)
- What “rebuild” work is expected to contribute
Plan for R&D to support 2027 (what management says is in place and what it is designed to achieve)
- R&D capability improvement is already visible in pipeline and development capacity
- R&D is explicitly linked to business evolution: Fine/Consumer through leadership of “gaps” and strengths
- Management’s “competitive position” expectation (time horizon extending beyond 2026)
- Product development and delivery systems as the tangible R&D output
Bottom line summary (directly answering your three parts)

Keep Reading

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

Sources used

Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?

Answer outline

Drivers of Scent’s recovery (what management attributes the turnaround to)
- Rebalancing and targeted reinvestment in Scent capabilities
- R&D pipeline and leadership reset (the “capability” driver)
- Fine Fragrance vs. Middle East volatility (a major near-term driver of the recovery path)
- Consumer Fragrance execution: rebuilding R&D and go-to-market to win share
- Fragrance Ingredients: strong Q2 performance, then normalization and mix shift
How Fine Fragrance and Consumer Fragrance will evolve in 2H 2026 (management’s directional growth view)
- Fine Fragrance (soft Q3, stronger Q4; trajectory into 2H mid-single digits)
- Consumer Fragrance (low single-digit normalization; Q2 was strong but should normalize)
- What “rebuild” work is expected to contribute
Plan for R&D to support 2027 (what management says is in place and what it is designed to achieve)
- R&D capability improvement is already visible in pipeline and development capacity
- R&D is explicitly linked to business evolution: Fine/Consumer through leadership of “gaps” and strengths
- Management’s “competitive position” expectation (time horizon extending beyond 2026)
- Product development and delivery systems as the tangible R&D output
Bottom line summary (directly answering your three parts)

IFF Signals Scent Recovery Driven by R&D Rebuild and 2027 Plan

Sources used

Research question

Answer

Drivers of Scent recovery, 2H evolution (Fine Fragrance vs. Consumer Fragrance), and the R&D plan to support 2027 (IFF)

1) Drivers of the Scent recovery

A. R&D “pipeline” rebuilt after being behind; stronger capability today

B. Market share gains and a strengthened go-to-market approach in Consumer Fragrance

C. Fine Fragrance: managed volatility from the Middle East; recovery expected to become clearer into Q4

D. Fragrance Ingredients strength acts as an important near-term tailwind (and is expected to normalize)

2) How Fine Fragrance and Consumer Fragrance are expected to evolve in the second half (2026)

Fine Fragrance (2H trajectory)

Consumer Fragrance (2H trajectory)

Fragrance Ingredients (important context for Scent recovery, and influences consolidated tone)

Summary table (directional evolution, using management’s language)

3) Plan for R&D to support 2027 (what the company says it is doing)

A. R&D capability and pipeline are now “strong,” enabling execution through 2027

B. Compounds/product platform and delivery systems are part of the execution engine

C. Ingredients strategy (higher-value natural products) takes longer—positioning improvement “next year and the year after”

D. R&D is embedded in a broader “reinvent and reinvest” cycle tied to innovation and market share

Integrated answer (directly to the question)

References

Keep Reading

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

Keep Reading

Keep Reading

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

IFF Scent Recovery Driven by R&D Rebuild; Q2 2026 H2 Outlook and 2027 Plan

IFF's Scent Recovery Q2 2026 Highlights, H2 Outlook and 2027 R&D Plan

IFF Scent Recovery Driven by R&D Rebuild, Fragrance Momentum, and 2027 Plan

IFF's Scent Recovery Driven by R&D Rebuild, 2027 Readiness Ahead

IFF Scent Recovery Driven by R&D Rebuild, H2 Outlook, and 2027 Plan

IFF Scent Recovery Gains Momentum as R&D Engine Strengthens for 2027 Plan

IFF's Scent Recovery Fueled by Fine and Consumer Fragrance; 2027 R&D Plan

IFF Scent Recovery Fueled by Fine Fragrance Management and 2027 R&D Plan

IFF Scent Recovery Gains Momentum in H2 2026, R&D Drives 2027 Plan

IFF Scent Recovery Gains Traction in 2H 2026, R&D Plan Supports 2027

IFF Scent Recovery Driven by R&D Upswing, 2H Fragrance Outlook, 2027 Plan